Publication:
Design of the β3-Adrenergic Agonist Treatment in Chronic Pulmonary Hypertension Secondary to Heart Failure Trial.

Simple item page
dc.contributor.authorGarcia-Lunar, Ines
dc.contributor.authorBlanco, Isabel
dc.contributor.authorFernandez-Friera, Leticia
dc.contributor.authorPrat-Gonzàlez, Susanna
dc.contributor.authorJordà, Paloma
dc.contributor.authorSánchez, Javier
dc.contributor.authorPereda, Daniel
dc.contributor.authorPujadas, Sandra
dc.contributor.authorRivas, Mercedes
dc.contributor.authorSolé-Gonzalez, Eduard
dc.contributor.authorVázquez, Jorge
dc.contributor.authorBlázquez, Zorba
dc.contributor.authorGarcía-Picart, Juan
dc.contributor.authorCaravaca, Pedro
dc.contributor.authorEscalera, Noemí
dc.contributor.authorGarcia-Pavia, Pablo
dc.contributor.authorDelgado, Juan
dc.contributor.authorSegovia-Cubero, Javier
dc.contributor.authorFuster, Valentin
dc.contributor.authorRoig, Eulalia
dc.contributor.authorBarberá, Joan Albert
dc.contributor.authorIbáñez, Borja
dc.contributor.authorGarcia-Alvarez, Ana
dc.contributor.funderFundación La Marató TV3
dc.contributor.funderMinisterio de Ciencia, Innovación y Universidades (España)
dc.contributor.funderFundación ProCNIC
dc.contributor.funderGovernment of Catalonia (España)
dc.date.accessioned2020-06-12T09:28:43Z
dc.date.available2020-06-12T09:28:43Z
dc.date.issued2020-04
dc.description.abstractCombined pre-and post-capillary hypertension (CpcPH) is a relatively common complication of heart failure (HF) associated with a poor prognosis. Currently, there is no specific therapy approved for this entity. Recently, treatment with beta-3 adrenergic receptor (β3AR) agonists was able to improve pulmonary hemodynamics and right ventricular (RV) performance in a translational, large animal model of chronic PH. The authors present the design of a phase II randomized clinical trial that tests the benefits of mirabegron (a clinically available β3AR agonist) in patients with CpcPH due to HF. The effect of β3AR treatment will be evaluated on pulmonary hemodynamics, as well as clinical, biochemical, and advanced cardiac imaging parameters. (Beta3 Agonist Treatment in Chronic Pulmonary Hypertension Secondary to Heart Failure [SPHERE-HF]; NCT02775539).es_ES
dc.description.peerreviewedSíes_ES
dc.description.sponsorshipThe SPHERE-HF trial is an investigator-initiated noncommercial trial independent of the pharmaceutical industry. This work was funded by a grant from Fundació La Marató de TV3 (20151730-31-32). The CNIC is supported by the Ministerio de Ciencia, Innovacion y Universidades and the Pro CNIC Foundation and is a Severo Ochoa Center of Excellence (SEV-2015-0505). IDIBAPS belongs to the CERCA Programme and receives partial funding from the Generalitat de Catalunya. Drs. Ibanez, García-Álvarez, and Fuster are co-inventors of a patent for the use of beta-3 agonists for the treatment of pulmonary hypertension.es_ES
dc.format.number4es_ES
dc.format.page317-327es_ES
dc.format.volume5es_ES
dc.identifier.citationJACC Basic Transl Sci. 2020; 5(4):317-327es_ES
dc.identifier.doi10.1016/j.jacbts.2020.01.009es_ES
dc.identifier.e-issn2452-302Xes_ES
dc.identifier.journalJACC. Basic to translational sciencees_ES
dc.identifier.pubmedID32368692es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/10375
dc.language.isoenges_ES
dc.publisherElsevieres_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/SEV-2015-0505es_ES
dc.relation.publisherversionhttps://doi.org/10.1016/j.jacbts.2020.01.009es_ES
dc.repisalud.institucionCNICes_ES
dc.repisalud.orgCNICCNIC::Grupos de investigación::Laboratorio Traslacional para la Imagen y Terapia Cardiovasculares_ES
dc.repisalud.orgCNICCNIC::Grupos de investigación::Imagen Cardiovascular y Estudios Poblacionaleses_ES
dc.rights.accessRightsopen accesses_ES
dc.rights.licenseAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.titleDesign of the β3-Adrenergic Agonist Treatment in Chronic Pulmonary Hypertension Secondary to Heart Failure Trial.es_ES
dc.typejournal articlees_ES
dc.type.hasVersionVoRes_ES
dspace.entity.typePublication
relation.isAuthorOfPublicationde903570-4c8c-4bcb-8cfe-d077154694e0
relation.isAuthorOfPublication4b2a0672-e9a0-4788-b256-d3170c84aab2
relation.isAuthorOfPublicationf24ff9e6-bd10-499d-8e3f-601b2fdc5238
relation.isAuthorOfPublication52ada1ee-7241-4738-b46d-90a5ccc14894
relation.isAuthorOfPublication558474d4-85be-4127-bda8-59128f707249
relation.isAuthorOfPublication2cac8bb6-2bff-4bf6-8209-bdbd21781786
relation.isAuthorOfPublication92018446-2b00-4798-a27d-d2b26871b81b
relation.isAuthorOfPublication.latestForDiscoveryde903570-4c8c-4bcb-8cfe-d077154694e0

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
DesignBeta3-AdrenergicAgonist_2020.pdf
Size:
1.13 MB
Format:
Adobe Portable Document Format
Description:
Artículo
Download

Collections

Grupos de investigación